Literature DB >> 28446569

Differentiated Levels of Ganciclovir Resistance Conferred by Mutations at Codons 591 to 603 of the Cytomegalovirus UL97 Kinase Gene.

Sunwen Chou1,2, Ronald J Ercolani2, Adam L Vanarsdall3.   

Abstract

Diagnostic mutations in the cytomegalovirus UL97 kinase gene are used to assess the level of associated ganciclovir resistance and therapeutic options. The best-known mutations at codons 460, 520, or 591 to 607 individually confer 5- to 10-fold-decreased ganciclovir susceptibility, except that a 3-fold decrease occurs in the case of the amino acid substitution C592G. Less common point and in-frame deletion mutations at codons 591 to 603 remain incompletely characterized. The ganciclovir susceptibilities of 17 mutants in this codon range were evaluated by use of the same recombinant phenotyping system and extensive assay replicates in two types of cell cultures. Amino acid substitutions K599E and T601M conferred no ganciclovir resistance, while A591V conferred 3.8-fold-decreased susceptibility. In-frame deletions of three or more codons conferred at least 8-fold-increased ganciclovir resistance, while the level of resistance conferred by one- or two-codon deletions varied from 4- to 10-fold, depending on their location. Measured levels of ganciclovir resistance were closely comparable when assays were performed in either fibroblasts or modified retinal epithelial cells. The significant revision of a few previously published resistance phenotypes and the new data strengthen the interpretation of genotypic testing for cytomegalovirus drug resistance.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  cytomegalovirus; drug resistance mechanisms; ganciclovir

Mesh:

Substances:

Year:  2017        PMID: 28446569      PMCID: PMC5483911          DOI: 10.1128/JCM.00391-17

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  40 in total

1.  Antiviral susceptibility testing of cytomegalovirus: criteria for detecting resistance to antivirals.

Authors:  W L Drew; R Miner; E Saleh
Journal:  Clin Diagn Virol       Date:  1993-08

2.  Identification of resistance-associated HCMV UL97- and UL54-mutations and a UL97-polymporphism with impact on phenotypic drug-resistance.

Authors:  Lena Fischer; Eike Imrich; Kerstin Laib Sampaio; Jörg Hofmann; Gerhard Jahn; Klaus Hamprecht; Katharina Göhring
Journal:  Antiviral Res       Date:  2016-04-04       Impact factor: 5.970

3.  Mutations in the UL97 ORF of ganciclovir-resistant clinical cytomegalovirus isolates differentially affect GCV phosphorylation as determined in a recombinant vaccinia virus system.

Authors:  Fausto Baldanti; Detlef Michel; Lavinia Simoncini; Maria Heuschmid; Albert Zimmermann; Rosalba Minisini; Peter Schaarschmidt; Thomas Schmid; Giuseppe Gerna; Thomas Mertens
Journal:  Antiviral Res       Date:  2002-04       Impact factor: 5.970

4.  Emergence of multiple drug-resistant human cytomegalovirus variants in 2 patients with human immunodeficiency virus infection unresponsive to highly active antiretroviral therapy.

Authors:  Fausto Baldanti; Stefania Paolucci; Aldo Parisi; Luca Meroni; Giuseppe Gerna
Journal:  Clin Infect Dis       Date:  2002-03-19       Impact factor: 9.079

Review 5.  Antiviral drug resistance of human cytomegalovirus.

Authors:  Nell S Lurain; Sunwen Chou
Journal:  Clin Microbiol Rev       Date:  2010-10       Impact factor: 26.132

6.  Cytomegalovirus resistance in solid organ transplant recipients treated with intravenous ganciclovir or oral valganciclovir.

Authors:  Guy Boivin; Nathalie Goyette; Halvor Rollag; Alan G Jardine; Mark D Pescovitz; Anders Asberg; Jane Ives; Anders Hartmann; Atul Humar
Journal:  Antivir Ther       Date:  2009

7.  A three-nucleotide deletion in the UL97 open reading frame is responsible for the ganciclovir resistance of a human cytomegalovirus clinical isolate.

Authors:  F Baldanti; E Silini; A Sarasini; C L Talarico; S C Stanat; K K Biron; M Furione; F Bono; G Palù; G Gerna
Journal:  J Virol       Date:  1995-02       Impact factor: 5.103

8.  Plasma and intracellular exposure to ganciclovir in adult renal transplant recipients: is there an association with haematological toxicity?

Authors:  Pierre-André Billat; Jean-Baptiste Woillard; Marie Essig; François-Ludovic Sauvage; Nicolas Picard; Sophie Alain; Michael Neely; Pierre Marquet; Franck Saint-Marcoux
Journal:  J Antimicrob Chemother       Date:  2015-11-03       Impact factor: 5.790

9.  Successful valganciclovir treatment of post-transplant cytomegalovirus infection in the presence of UL97 mutation N597D.

Authors:  Jenna M Iwasenko; Gillian M Scott; William D Rawlinson; Anne Keogh; Daniel Mitchell; Sunwen Chou
Journal:  J Med Virol       Date:  2009-03       Impact factor: 2.327

10.  PDGF receptor-α does not promote HCMV entry into epithelial and endothelial cells but increased quantities stimulate entry by an abnormal pathway.

Authors:  Adam L Vanarsdall; Todd W Wisner; Hetian Lei; Andrius Kazlauskas; David C Johnson
Journal:  PLoS Pathog       Date:  2012-09-13       Impact factor: 6.823

View more
  11 in total

1.  Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds.

Authors:  Sunwen Chou
Journal:  Antimicrob Agents Chemother       Date:  2017-10-24       Impact factor: 5.191

2.  New Locus of Drug Resistance in the Human Cytomegalovirus UL56 Gene Revealed by In Vitro Exposure to Letermovir and Ganciclovir.

Authors:  Sunwen Chou; L Elizabeth Satterwhite; Ronald J Ercolani
Journal:  Antimicrob Agents Chemother       Date:  2018-08-27       Impact factor: 5.191

3.  Patient-Derived Cytomegaloviruses with Different Ganciclovir Sensitivities from UL97 Mutation Retain Their Replication Efficiency and Some Kinase Activity In Vitro.

Authors:  Diana D Wong; Wendy J van Zuylen; Stuart T Hamilton; Mirjam Steingruber; Eric Sonntag; Manfred Marschall; William D Rawlinson
Journal:  Antimicrob Agents Chemother       Date:  2019-08-23       Impact factor: 5.191

4.  Novel UL97 drug resistance mutations identified at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infection.

Authors:  Sunwen Chou; Jingyang Wu; Kening Song; Tien Bo
Journal:  Antiviral Res       Date:  2019-09-27       Impact factor: 5.970

5.  Letermovir Resistance Analysis in a Clinical Trial of Cytomegalovirus Prophylaxis for Hematopoietic Stem Cell Transplant Recipients.

Authors:  Cameron M Douglas; Richard Barnard; Daniel Holder; Randi Leavitt; Diane Levitan; Maureen Maguire; David Nickle; Valerie Teal; Hong Wan; Dirk C J G van Alewijk; Leen-Jan van Doorn; Sunwen Chou; Julie Strizki
Journal:  J Infect Dis       Date:  2020-03-16       Impact factor: 5.226

6.  A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance.

Authors:  Sunwen Chou
Journal:  Antiviral Res       Date:  2017-10-28       Impact factor: 5.970

7.  Antiviral activity of maribavir in combination with other drugs active against human cytomegalovirus.

Authors:  Sunwen Chou; Ronald J Ercolani; Katayoun Derakhchan
Journal:  Antiviral Res       Date:  2018-07-21       Impact factor: 5.970

Review 8.  Advances in the genotypic diagnosis of cytomegalovirus antiviral drug resistance.

Authors:  Sunwen Chou
Journal:  Antiviral Res       Date:  2020-01-12       Impact factor: 5.970

9.  Opposite effects of cytomegalovirus UL54 exonuclease domain mutations on acyclovir and cidofovir susceptibility.

Authors:  Sunwen Chou
Journal:  Antiviral Res       Date:  2021-09-21       Impact factor: 5.970

10.  Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands.

Authors:  Coretta C Van Leer Buter; Danielle W K de Voogd; Hans Blokzijl; Anoek A E de Joode; Stefan P Berger; Erik A M Verschuuren; Hubert G M Niesters
Journal:  J Antimicrob Chemother       Date:  2019-08-01       Impact factor: 5.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.